Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT03907488 |
| Title | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | National Cancer Institute (NCI) |
| Indications |
Hodgkin's lymphoma, lymphocytic depletion Hodgkin's lymphoma, nodular sclerosis |
| Therapies |
Brentuximab vedotin + Dacarbazine + Doxorubicin + Vinblastine |
| Age Groups: | adult | child | senior |
| Covered Countries | USA | CAN |